Function Therapeutics has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI)
The grant is titled “Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease”. This project focuses on the development of the new parmodulin class of anti-inflammatory compounds, and their testing in models of this blood and vascular disease that can make daily life extremely challenging (and dangerous) for hundreds of thousands worldwide. This project is a collaboration with Dr. Erica Sparkenbaugh at the University of North Carolina, whose lab has performed important work to demonstrate the protective ability of parmodulins in vascular disease.